The consumer-focused investment firm has led the Series A for Remedy Science, a dermatologist-developed skincare brand founded by Dr. Muneeb Shah.
Remedy was created to mirror the way dermatologists approach skin in clinic: starting with the patient concern, meticulously formulating to create advanced solutions, and prioritizing visible results without compromising skin health. The brand’s portfolio addresses the concerns dermatologists see every day, including dark spots, dryness, fine lines, dullness, keratosis pilaris, and sensitive skin.
Remedy has grown exponentially since launching in March 2024, recording significant growth across all online channels, its direct-to-consumer website, Amazon, and TikTok Shop. The business also has seen breakout success in Target following its December 2025 nationwide launch in the retailer.
“For years, I saw patients who were doing everything right but still struggling to find products that delivered meaningful results without irritation or unnecessary complexity. Remedy was created to modernize dermatologist-developed skincare,” said Dr. Muneeb Shah, founder and CEO of Remedy. "Each formula starts with a real patient need. We then innovate with the latest ingredient technologies to create clinically tested, high-efficacy formulas with a focus on visible results and safety for sensitive skin.”
“We believe Remedy is defining the future of dermatologist-developed skincare,” said Tehmina Haider, Partner at L Catterton. "As both a clinician and a consumer educator, Dr. Shah has built a portfolio of simple, effective, and accessibly priced products that leverage advanced ingredient technologies to address real patient needs — and that is what will define the next generation of dermocosmetics. The brand’s rapid growth reflects deep consumer demand for affordable, clinically-grounded skincare, and we are thrilled to partner with the Remedy team on their next chapter."
The Series A investment will support Remedy’s next phase of growth, including advancing clinical research, expanding its pipeline of dermatologist-developed products, building a best-in-class team and improving inventory depth to meet increasing demand across DTC, Amazon, and Target. The company also plans to deepen its capabilities across formulation, testing, and consumer education as it continues building a scaled dermocosmetic platform.
